AssetMark’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$368K Buy
5,584
+789
+16% +$60.2K ﹤0.01% 1310
2026
Q2
$408K Buy
4,795
+1,332
+38% +$95.6K ﹤0.01% 1279
2026
Q1
$228K Buy
3,463
+438
+14% +$27.8K ﹤0.01% 1321
2025
Q4
$192K Sell
3,025
-338
-10% -$21K ﹤0.01% 1318
2025
Q3
$185K Buy
3,363
+721
+27% +$29.7K ﹤0.01% 1282
2025
Q2
$87.3K Buy
2,642
+1,481
+128% +$51.5K ﹤0.01% 1399
2025
Q1
$46.7K Buy
1,161
+1,151
+11,510% +$52.9K ﹤0.01% 1457
2024
Q4
$470 Buy
+10
New +$519 ﹤0.01% 2383
2024
Q1
– Sell
-4
Closed -$334 – 1974
2023
Q4
$334 Buy
+4
New +$145 ﹤0.01% 1712
2018
Q1
– Sell
-15
Closed – – 1543
2017
Q4
$0 Buy
+15
New +$170 ﹤0.01% 1920
2017
Q1
– Sell
-34
Closed – – 1295
2016
Q4
$0 Buy
+34
New +$361 ﹤0.01% 1266

Other funds holding CYTK

AssetMark's CYTK Position: Q3 2026 in Review

AssetMark increased its Cytokinetics (CYTK) stake by 16% in Q3 2026, buying an estimated $60.2K and bringing the position to 5,584 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

AssetMark first reported a position in CYTK in Q4 2016 and has held it in 11 quarters since. The position peaked at $408K in Q2 2026. 354 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • AssetMark held 5,584 shares of Cytokinetics worth $368K as of Q3 2026.
  • AssetMark bought 789 Cytokinetics shares in Q3 2026, an estimated $60.2K.
  • Cytokinetics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1310 holding.
  • AssetMark first reported a position in Cytokinetics in Q4 2016 and has held it in 11 quarters since.
  • AssetMark's Cytokinetics position peaked at $408K in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.